Replies to post #273224 on Avid Bioservices Inc (CDMO)

[onco]

I am quite comfortable that there is such a subgroup you see it in many cancer studies. The exciting thing here is the identification of a marker this is huge if the subset is large enough and/or OS great enough the FDA a may be kind enough to act. IMHO

[Wildhorses]

IFU,

"Theoretically, couldn't there be a subset of patients from the [B+D] Arm with the bio-marker which generated a statistically significant OS when compared to the entire [D+P] Arm?

Winner, winner, chicken dinner! Only addition is:

"with the bio-maker which generated a statistically significant OS improvement"

Anyway, that's my story and I'm sticking to it.

I just find it atrocious that PPHM won't release the subset data before the scheduled proffered presentation. Obviously it must be bad.

Sorry, I just had to write that last bit to see if it sounded as stupid when I say it as it does when I hear it.

Regards,

WH